Darwin Global Management Ltd. Grows Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS)

Darwin Global Management Ltd. grew its holdings in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 10.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,687,135 shares of the company's stock after acquiring an additional 163,403 shares during the period. Keros Therapeutics accounts for approximately 2.5% of Darwin Global Management Ltd.'s investment portfolio, making the stock its 5th biggest holding. Darwin Global Management Ltd. owned approximately 4.16% of Keros Therapeutics worth $26,707,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. AlphaQuest LLC lifted its stake in Keros Therapeutics by 469.0% in the fourth quarter. AlphaQuest LLC now owns 3,596 shares of the company's stock valued at $57,000 after buying an additional 2,964 shares during the period. Virtus ETF Advisers LLC lifted its position in shares of Keros Therapeutics by 107.5% during the 4th quarter. Virtus ETF Advisers LLC now owns 3,857 shares of the company's stock valued at $61,000 after acquiring an additional 1,998 shares during the period. KLP Kapitalforvaltning AS bought a new position in Keros Therapeutics during the fourth quarter worth $90,000. Exchange Traded Concepts LLC acquired a new stake in Keros Therapeutics in the fourth quarter worth $99,000. Finally, CANADA LIFE ASSURANCE Co increased its stake in Keros Therapeutics by 207.8% in the fourth quarter. CANADA LIFE ASSURANCE Co now owns 7,371 shares of the company's stock valued at $116,000 after purchasing an additional 4,976 shares in the last quarter. 71.56% of the stock is owned by institutional investors.

Keros Therapeutics Stock Up 0.5 %

Shares of NASDAQ:KROS traded up $0.08 on Friday, hitting $14.65. The company had a trading volume of 651,753 shares, compared to its average volume of 811,465. The firm has a market capitalization of $594.95 million, a price-to-earnings ratio of -2.81 and a beta of 1.32. The firm's 50-day simple moving average is $11.92 and its two-hundred day simple moving average is $26.07. Keros Therapeutics, Inc. has a 1 year low of $9.12 and a 1 year high of $72.37.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last announced its quarterly earnings results on Wednesday, February 26th. The company reported ($1.14) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.36) by $0.22. The company had revenue of $3.04 million for the quarter, compared to analysts' expectations of $37.32 million. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. Equities research analysts anticipate that Keros Therapeutics, Inc. will post -4.74 EPS for the current year.

Insiders Place Their Bets

In other news, major shareholder Adar1 Capital Management, Llc bought 934,258 shares of Keros Therapeutics stock in a transaction that occurred on Wednesday, April 9th. The stock was bought at an average cost of $10.13 per share, with a total value of $9,464,033.54. Following the acquisition, the insider now owns 4,392,737 shares of the company's stock, valued at $44,498,425.81. The trade was a 27.01 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 22.90% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several analysts have recently commented on KROS shares. Truist Financial reduced their target price on Keros Therapeutics from $43.00 to $25.00 and set a "buy" rating for the company in a research note on Wednesday, April 9th. Scotiabank cut their price objective on shares of Keros Therapeutics from $44.00 to $41.00 and set a "sector outperform" rating on the stock in a report on Thursday, January 16th. Oppenheimer decreased their price objective on shares of Keros Therapeutics from $63.00 to $23.00 and set an "outperform" rating for the company in a report on Thursday, January 16th. Wells Fargo & Company reduced their target price on shares of Keros Therapeutics from $28.00 to $26.00 and set an "overweight" rating for the company in a research note on Thursday, February 27th. Finally, Cantor Fitzgerald cut shares of Keros Therapeutics from an "overweight" rating to a "neutral" rating in a research note on Tuesday, January 21st. Six research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, Keros Therapeutics presently has a consensus rating of "Moderate Buy" and an average price target of $40.33.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.